Global Botulinum Toxins Market Size Will Reach $59.33 Billion in 2024

Global Botulinum Toxins Market Overview

According to Global Market Monitor, the global botulinum toxins market size will reach $59.33 billion in 2024 with a CAGR of 9.67% from 2024 to 2029.

North America Dominates the Market.

North America held the largest market share – 51.27% in 2023. According to the American Society of Plastic Surgeons (ASPS), a million surgeries are performed with botulinum toxin products. Thus, increasing the use of botulinum toxin products in various cosmetic procedures performed in the region will stimulate the North American botulinum toxin industry growth.

Asia Pacific will witness significant growth owing to favorable reimbursement, a large patient population, and the availability of developed healthcare facilities in many countries. In countries, like South Korea, China, and Japan, there is higher beauty consciousness and aesthetic awareness, hence likely to drive the market growth. Furthermore, there is a rising number of medical spas and cosmetic centers in countries like Thailand, Singapore, and Malaysia. These are the factors that are expected to drive the botulinum toxin sector in the region.

The increasing usage of botulinum toxin injection in several aesthetic procedures including treating glabellar lines, chemical brow lifts, forehead lines, and others is expected to boost the botulinum toxin industry growth over the coming years. Rising investment in R&D programs by major manufacturers to explore the therapeutic use of botulinum toxin is building opportunities to expand its therapeutic application area shortly.   Minimally invasive procedures offer advantages such as smaller incisions, shorter hospital stays, quick outpatient services, rapid wound healing, lesser pain, and lower risk of complications than invasive surgeries.   

Allergan plc is one of the major players operating in the Botulinum Toxins market, holding a share of 67.58% in 2023.Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women’s health, and anti-infective therapeutic products.

Company Name	Allergan plc
Website	www.allergan.com
Established Time	1983
Sales Region	Europe, North America, Asia-Pacific, South America, Middle East, Africa
Product Overview	Botox, the first approved Botox type A product and the most approved neurotoxin in the world was approved by the FDA in 1989 for the treatment of blepharospasm and strabismus. Botox is approved in over 100 countries and produces over 100 million bottles worldwide.